Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Gastroenterology | Internal Medicine | Nursing | Oncology | Surgery | Journal

Back to Journal Articles

Pancreatectomy OK Without Downstaging From Therapy

Last Updated: May 25, 2012.

 

Radiographic downstaging rare even after neoadjuvant therapy in pancreatic cancer patients

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May 17 in Cancer.

FRIDAY, May 25 (HealthDay News) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published online May 17 in Cancer.

Matthew H.G. Katz, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues studied 129 patients who had borderline resectable pancreatic cancer. Patients received neoadjuvant therapy prior to undergoing surgery. To determine changes in tumor size or stage using modified Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), the researchers reviewed computed tomography images both pre- and post-treatment.

The researchers found that, of the 122 patients who had their disease restaged after receiving preoperative therapy, 15 patients (12 percent) had a partial response to therapy, 23 patients (19 percent) had progressive disease, and 84 patients (69 percent) had stable disease. Eighty-five patients (66 percent) underwent pancreatectomy, and only one patient had their disease downstaged to resectable status after neoadjuvant therapy. The median overall survival for all 129 patients was 22 months; however, median overall survival was 33 months for those patients who underwent pancreatectomy.

"Radiographic downstaging was rare after neoadjuvant therapy, and RECIST response was not an effective treatment end point for patients with borderline resectable pancreatic cancer," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Selenium and/or Vitamin E Do Not Prevent Bladder Cancer Next: Interneuron Transplant Treats Neuropathic Pain in Mice

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.